Galectin Therapeutics Inc.
GALTDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How GALT's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
belapectin | Phase 3 | Prevention of Esophageal Varices | - | - |
GR-MD-02 | Phase 2 | Psoriasis | - | - |
Frequently asked questions
What is in Galectin Therapeutics Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Galectin Therapeutics Inc.'s (GALT) pipeline across Phase 3, Phase 2. Its lead program is belapectin (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Galectin Therapeutics Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Galectin Therapeutics Inc. (GALT) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track GALT biotech catalysts?→
Add GALT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Galectin Therapeutics Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.